These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Johnson DB; Friedman DL; Berry E; Decker I; Ye F; Zhao S; Morgans AK; Puzanov I; Sosman JA; Lovly CM Cancer Immunol Res; 2015 May; 3(5):464-9. PubMed ID: 25649350 [TBL] [Abstract][Full Text] [Related]
63. ANCA-associated vasculitic neuropathy during treatment with ipilimumab. Villarreal-Compagny M; Iglesias P; Marco-Hernández J; Milisenda JC; Casanova-Molla J; Hernández-Rodríguez J; Puig S; Carrera C; Prieto-González S Rheumatology (Oxford); 2020 Jan; 59(1):251-252. PubMed ID: 31209477 [No Abstract] [Full Text] [Related]
64. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Torino F; Barnabei A; De Vecchis L; Salvatori R; Corsello SM Oncologist; 2012; 17(4):525-35. PubMed ID: 22477725 [TBL] [Abstract][Full Text] [Related]
65. Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings. Cervantes J; Rosen A; Dehesa L; Dickinson G; Alonso-Llamazares J Actas Dermosifiliogr (Engl Ed); 2019; 110(1):43-49. PubMed ID: 30389125 [TBL] [Abstract][Full Text] [Related]
66. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis. Thapi S; Leiter A; Galsky M; Gallagher EJ J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065 [TBL] [Abstract][Full Text] [Related]
67. Pituitary-related immune adverse events induced by programmed death Protein-1 inhibitors differ clinically from hypophysitis. Yang L; Zhang Y; Chen X; Liu K; Zhou Y; Wang S Clin Endocrinol (Oxf); 2024 Aug; 101(2):130-139. PubMed ID: 38753540 [TBL] [Abstract][Full Text] [Related]
68. [Endocrine side effects of checkpoint inhibitors]. Chen WJY; Krul-Poel YHM; Roth C; Labots M; van den Eertwegh AJM; Dreijerink KMA Ned Tijdschr Geneeskd; 2019 Oct; 163():. PubMed ID: 31714042 [TBL] [Abstract][Full Text] [Related]
69. Ipilimumab- and nivolumab-associated enterocolitis with florid necrotising granulomatous inflammation: a novel manifestation of 'immunomodulatory' enterocolitis. Paton DJW; Warburton L; Chung K; Meniawy TM; Kumarasinghe MP Pathology; 2018 Jun; 50(4):466-469. PubMed ID: 29735170 [No Abstract] [Full Text] [Related]
70. Hypophysitis secondary to pembrolizumab: a case report and review of the literature. Montero Pérez O; Sánchez Escudero L; Guzmán Ramos MI; Aviñó Tarazona V Anticancer Drugs; 2022 Jan; 33(1):94-99. PubMed ID: 34261922 [TBL] [Abstract][Full Text] [Related]
71. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors. Fernandes S; Varlamov EV; McCartney S; Fleseriu M Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478 [TBL] [Abstract][Full Text] [Related]
72. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature. Abdallah AO; Herlopian A; Ravilla R; Bansal M; Chandra-Reddy S; Mahmoud F; Ong S; Gokden M; Hutchins L J Oncol Pharm Pract; 2016 Jun; 22(3):537-42. PubMed ID: 25712627 [TBL] [Abstract][Full Text] [Related]
73. Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management. Tiu C; Pezaro C; Davis ID; Grossmann M; Parente P Asia Pac J Clin Oncol; 2015 Jun; 11(2):190-4. PubMed ID: 25855890 [TBL] [Abstract][Full Text] [Related]
75. Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies. Tsoli M; Kaltsas G; Angelousi A; Alexandraki K; Randeva H; Kassi E Cancer Manag Res; 2020; 12():9551-9561. PubMed ID: 33061641 [TBL] [Abstract][Full Text] [Related]
76. A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment. Humayun MA; Poole R Hormones (Athens); 2016 Apr; 15(2):303-306. PubMed ID: 27376434 [No Abstract] [Full Text] [Related]
77. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465 [TBL] [Abstract][Full Text] [Related]
78. Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. Sood A; Cole D; Abdollah F; Eilender B; Roumayah Z; Deebajah M; Dabaja A; Alanee S Curr Urol Rep; 2018 Jul; 19(9):68. PubMed ID: 29971696 [TBL] [Abstract][Full Text] [Related]
79. Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia. Maeda T; Hiura A; Uehara J; Toyoshima R; Nakagawa T; Yoshino K Eur J Dermatol; 2021 Oct; 31(5):662-664. PubMed ID: 34642136 [No Abstract] [Full Text] [Related]